Arrowhead Pharmaceuticals to Present Interim ARO-MAPT Data in Phase…

Event summary

Arrowhead Pharmaceuticals will host an R&D webinar on October 14, 2026, to present interim data from the Phase 1/2a study of ARO-MAPT for Alzheimer’s disease and other tauopathies.
ARO-MAPT is an investigational RNAi therapeutic designed to silence the MAPT gene, targeting tau protein accumulation in neurodegenerative diseases.
The AROMAPT-SC-1001 study includes up to 64 healthy volunteers and 48 early Alzheimer’s patients, evaluating safety, tolerability, and pharmacodynamics.
Arrowhead’s TRiM™ platform enables subcutaneous delivery of siRNA to the central nervous system, showcasing its leadership in RNAi therapeutics.

The big picture

Arrowhead Pharmaceuticals is positioning itself at the forefront of RNAi therapeutics with its proprietary TRiM™ platform, which enables targeted delivery of siRNA to the central nervous system. The upcoming webinar on ARO-MAPT interim data is a critical milestone in assessing the potential of this therapeutic approach for Alzheimer’s disease and other tauopathies. The success of this program could validate Arrowhead’s technology and strengthen its competitive edge in the biotechnology sector.

What we're watching

Clinical Efficacy: How the interim data from the Phase 1/2a study will impact the perceived viability of ARO-MAPT as a potential treatment for Alzheimer’s disease.
Market Positioning: Whether Arrowhead can sustain its leadership in RNAi therapeutics with successful CNS delivery through its TRiM™ platform.
Regulatory Pathway: The pace at which Arrowhead can advance ARO-MAPT through subsequent clinical phases and potential regulatory approvals.